Acadia Healthcare’s (ACHC) for-profit chain of 165 methadone clinics has generated more than $1.3B in revenue since 2022 and is “a business that we continue to feel great about,” Acadia’s CEO told investors this year, but a New York Times investigation found that business “has been built in part on deception,” according to a report published on December 7 by Katie Thomas and Jessica Silver-Greenberg. Acadia “often fails” to provide required counseling, according to five dozen current and former employees in 22 of the 33 states where the company has clinics, and “employees at times falsify the medical records that Acadia uses to bill insurers,” according to the employees and internal emails, the reporters stated.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare price target lowered to $43 from $76 at Barclays
- Acadia Healthcare price target lowered to $64 from $94 at RBC Capital
- Acadia Healthcare price target lowered to $70 from $91 at TD Cowen
- Acadia Healthcare price target lowered to $45 from $75 at Deutsche Bank
- Acadia Healthcare Reports Strong Q3 2024 Results